The NeoRes trial: questioning the benefit of radiation therapy as part of neoadjuvant therapy for esophageal adenocarcinoma.
作者信息
Stiles Brendon M, Altorki Nasser K
机构信息
Department of Cardiothoracic Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.
出版信息
J Thorac Dis. 2017 Oct;9(10):3465-3468. doi: 10.21037/jtd.2017.08.146.
Abstract
摘要
相似文献
1
The NeoRes trial: questioning the benefit of radiation therapy as part of neoadjuvant therapy for esophageal adenocarcinoma.NeoRes试验：质疑放射治疗作为食管腺癌新辅助治疗一部分的益处。
J Thorac Dis. 2017 Oct;9(10):3465-3468. doi: 10.21037/jtd.2017.08.146.
2
Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial).食管癌新辅助化疗或放化疗加手术随机临床试验中的健康相关生活质量（NeoRes 试验）。
Br J Surg. 2019 Oct;106(11):1452-1463. doi: 10.1002/bjs.11246. Epub 2019 Aug 22.
3
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.新辅助化疗与新辅助放化疗治疗食管或胃食管交界处癌：一项随机临床试验的长期结果。
Dis Esophagus. 2019 Feb 1;32(2). doi: 10.1093/dote/doy078.
4
ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).ESOPEC：一项前瞻性随机对照多中心III期试验，比较围手术期化疗（FLOT方案）与新辅助放化疗（CROSS方案）用于食管癌患者（NCT02509286）。
BMC Cancer. 2016 Jul 19;16:503. doi: 10.1186/s12885-016-2564-y.
5
Effects of neoadjuvant chemoradiotherapy vs chemotherapy alone on the relief of dysphagia in esophageal cancer patients: secondary endpoint analysis in a randomized trial.新辅助放化疗与单纯化疗对食管癌患者吞咽困难缓解的影响：一项随机试验的次要终点分析。
Dis Esophagus. 2019 Feb 1;32(2). doi: 10.1093/dote/doy069.
6
Pulmonary function and cardiac stress test after multimodality treatment of esophageal cancer.食管癌多模态治疗后的肺功能和心脏应激试验
Pract Radiat Oncol. 2016 May-Jun;6(3):e53-e59. doi: 10.1016/j.prro.2015.10.015. Epub 2015 Nov 10.
7
Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.临床分期为淋巴结阴性的食管腺癌与新辅助放化疗带来的总生存获益之间的关联
JAMA Surg. 2016 Mar;151(3):234-45. doi: 10.1001/jamasurg.2015.4068.
8
Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.术前采用紫杉醇、卡铂、延长输注5-氟尿嘧啶联合放疗治疗局部食管癌：米妮·珀尔癌症研究网络II期试验的初步结果
Cancer J Sci Am. 1999 Mar-Apr;5(2):84-91.
9
The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma.新辅助放疗和淋巴结清扫术在食管腺癌治疗中的作用。
Ann Surg Oncol. 2010 Mar;17(3):791-803. doi: 10.1245/s10434-009-0819-4. Epub 2009 Dec 2.
10
NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy.食管腺癌中核因子-κB的激活：与巴雷特化生、生存率及新辅助放化疗反应的关系
Ann Surg. 2004 Apr;239(4):491-500. doi: 10.1097/01.sla.0000118751.95179.c6.
引用本文的文献
1
Preoperative radiotherapy in patients with locally advanced esophageal squamous cell carcinoma: a narrative review.局部晚期食管鳞状细胞癌患者的术前放疗：一项叙述性综述
Front Oncol. 2025 Jul 22;15:1613954. doi: 10.3389/fonc.2025.1613954. eCollection 2025.
2
Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced oesophageal squamous cell carcinoma: a protocol for a randomised controlled trial.吡非尼酮预防局部晚期食管鳞癌患者放射性肺损伤的随机对照试验方案。
BMJ Open. 2022 Oct 27;12(10):e060619. doi: 10.1136/bmjopen-2021-060619.
3
The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer.: a NCDB analysis.治疗 cT1N+ 和 cT2Nany 期食管癌的理想方法：NCDB 分析。
BMC Cancer. 2021 Dec 15;21(1):1334. doi: 10.1186/s12885-021-08896-0.
4
Shifting sands: the role of radiotherapy for patients with gastric and gastroesophageal adenocarcinoma.变幻莫测：放射治疗在胃及胃食管腺癌患者中的作用
Transl Gastroenterol Hepatol. 2021 Jul 25;6:50. doi: 10.21037/tgh.2020.03.01. eCollection 2021.
本文引用的文献
1
ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).ESOPEC：一项前瞻性随机对照多中心III期试验，比较围手术期化疗（FLOT方案）与新辅助放化疗（CROSS方案）用于食管癌患者（NCT02509286）。
BMC Cancer. 2016 Jul 19;16:503. doi: 10.1186/s12885-016-2564-y.
2
Preoperative Chemoradiation Therapy Versus Chemotherapy in Patients Undergoing Modified En Bloc Esophagectomy for Locally Advanced Esophageal Adenocarcinoma: Is Radiotherapy Beneficial?术前放化疗与单纯化疗用于局部晚期食管腺癌改良整块食管切除术患者的疗效比较：放疗是否有益？
Ann Thorac Surg. 2016 Apr;101(4):1262-9; discussion 1969-70. doi: 10.1016/j.athoracsur.2015.11.070. Epub 2016 Feb 23.
3
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.一项关于新辅助化疗与新辅助放化疗治疗食管癌或胃食管交界癌的随机临床试验。
Ann Oncol. 2016 Apr;27(4):660-7. doi: 10.1093/annonc/mdw010. Epub 2016 Jan 17.
4
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.新辅助放化疗联合手术与单纯手术治疗食管或食管胃交界癌（CROSS）：一项随机对照临床试验的长期结果。
Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.
5
Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.食管癌和胃食管交界部癌手术后的发病率和死亡率：新辅助化疗与新辅助放化疗的随机临床试验
Eur J Surg Oncol. 2015 Jul;41(7):920-6. doi: 10.1016/j.ejso.2015.03.226. Epub 2015 Apr 8.
6
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.NeoFLOT：可切除胃食管交界处腺癌或胃腺癌围手术期化疗的多中心 II 期研究-具有良好的反应，主要在肠型肿瘤患者中。
Int J Cancer. 2015 Aug 1;137(3):678-85. doi: 10.1002/ijc.29403. Epub 2015 Feb 25.
7
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.手术与放化疗后手术治疗Ⅰ期和Ⅱ期食管癌的比较：FFCD 9901 期随机对照Ⅲ期试验的最终分析。
J Clin Oncol. 2014 Aug 10;32(23):2416-22. doi: 10.1200/JCO.2013.53.6532. Epub 2014 Jun 30.
8
Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers.可切除食管和胃食管交界处癌症患者接受新辅助化疗或放化疗的术后发病率和围手术期死亡率的荟萃分析。
Br J Surg. 2014 Mar;101(4):321-38. doi: 10.1002/bjs.9418. Epub 2014 Feb 3.
9
Preoperative chemoradiotherapy for esophageal or junctional cancer.术前放化疗治疗食管或食管胃交界癌。
N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.
10
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.可切除食管癌新辅助化疗或放化疗后的生存：更新的荟萃分析。
Lancet Oncol. 2011 Jul;12(7):681-92. doi: 10.1016/S1470-2045(11)70142-5. Epub 2011 Jun 16.
Zotero 插件